Tian Yu, Chen Rong, Su Zhaoliang
International Genome Center, Jiangsu University, 301 Xuefu Road, Zhenjiang, 212013, Jiangsu, China.
Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, 212013, China.
Cell Mol Neurobiol. 2023 Jan;43(1):47-58. doi: 10.1007/s10571-021-01170-8. Epub 2021 Nov 19.
Parkinson's disease (PD) is one of the most common degenerative diseases of the human nervous system and has a wide range of serious impacts on human health and quality of life. Recently, research targeting high mobility group box 1 (HMGB1) in PD has emerged, and a variety of laboratory methods for inhibiting HMGB1 have achieved good results to a certain extent. However, given that HMGB1 undergoes a variety of intracellular modifications and three different forms of extracellular redox, the possible roles of these forms in PD are likely to be different. General inhibition of all forms of HMGB1 is obviously not ideal and has become one of the biggest obstacles in the clinical application of targeting HMGB1. In this review, pure mechanistic research of HMGB1 and in vivo research targeting HMGB1 were combined, the effects of HMGB1 on neurons and immune cell responses in PD are discussed in detail, and the problems that need to be focused on in the future are addressed.
帕金森病（PD）是人类神经系统最常见的退行性疾病之一，对人类健康和生活质量有着广泛而严重的影响。近年来，针对帕金森病中高迁移率族蛋白B1（HMGB1）的研究不断涌现，多种抑制HMGB1的实验室方法在一定程度上取得了良好效果。然而，鉴于HMGB1在细胞内会发生多种修饰，在细胞外存在三种不同形式的氧化还原状态，这些形式在帕金森病中可能发挥不同的作用。对所有形式的HMGB1进行一般性抑制显然并不理想，这已成为靶向HMGB1临床应用的最大障碍之一。在本综述中，将HMGB1的纯机制研究与靶向HMGB1的体内研究相结合，详细讨论了HMGB1对帕金森病中神经元和免疫细胞反应的影响，并探讨了未来需要关注的问题。
